You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 19, 2024

Details for Patent: 8,999,393

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,999,393 protect, and when does it expire?

Patent 8,999,393 protects LOREEV XR and is included in one NDA.

This patent has thirty-five patent family members in thirty countries.

Summary for Patent: 8,999,393

Title:	Sustained release formulations of lorazepam
Abstract:	A pharmaceutical composition for delivering lorazepam in a prolonged fashion is achieved with prolonged release lorazepam pharmaceutical beads. The composition typically contains sustained release lorazepam beads and delayed sustained release lorazepam beads. The composition can provide once daily dosing that maintains 24 hour therapeutic effect under steady state conditions.
Inventor(s):	Saltel; Douglas A. (Austin, TX), Vachon; Michael (Quebec, CA)
Assignee:	Edgemont Pharmaceuticals LLC (Austin, TX)
Application Number:	14/150,375
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,999,393

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Almatica	LOREEV XR	lorazepam	CAPSULE, EXTENDED RELEASE;ORAL	214826-001	Aug 27, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS	⤷ Sign Up
Almatica	LOREEV XR	lorazepam	CAPSULE, EXTENDED RELEASE;ORAL	214826-004	Feb 16, 2022		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS	⤷ Sign Up
Almatica	LOREEV XR	lorazepam	CAPSULE, EXTENDED RELEASE;ORAL	214826-002	Aug 27, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS	⤷ Sign Up
Almatica	LOREEV XR	lorazepam	CAPSULE, EXTENDED RELEASE;ORAL	214826-003	Aug 27, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,999,393

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	094391	⤷ Sign Up
Australia	2014205440	⤷ Sign Up
Brazil	112015016304	⤷ Sign Up
Canada	2897302	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.